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ABSTRACT
Background: 5-fluorouracil (5-FU) based chemotherapy is the most common first 
line regimen used in gastric and gastroesophageal junction cancer, but development 
of severe toxicity is a main concern in the  treatment. The present study is aimed to 
evaluate a novel pre-treatment assay, known as the 5-FU degradation rate (5-FUDR), 
as a predictive factor for 5-FU toxicity. 
Methods:  Pre-treatment 5-FUDR and gene polymorphisms related to 5-FU 
metabolism (DPYDIVS14+1G>A, MTHFRA1298T or C677T, TMYS TSER) were 
characterized in gastro-esophageal cancer patients. Association with toxicities was 
retrospectively evaluated, using multivariate logistic regression analysis. 
Results: 107 gastro-esophageal cancer patients were retrospectively analyzed. 
No relation between gene polymorphisms and toxicity were detected, while low (< 
5th centile) and high (> 95th centile) 5-FUDRs were associated with development of 
grade 3-4 toxicity (OR 11.14, 95% CI 1.09-113.77 and OR 9.63, 95% CI 1.70-54.55, 
p = 0.002). 
Conclusions: Compared to currently used genetic tests, the pre-treatment 5-FUDR 
seems useful in identifying patients at risk of developing toxicity.
Mini-abstract: 
 5-FUDR is a phenotypic test to pre-emptively classify patients in different 
metabolic classes. Patients with poor or ultra-rapid metabolism show significantly 
higher probability of developing severe toxicity during 5-FU treatment.
INTRODUCTION
5-Fluorouracil (5-FU) and its pro-drug capecitabine, 
alone or in combination with epirubicin, oxaliplatin, 
irinotecan, represent the most used chemotherapy 
treatments of gastroesophageal cancer, in both the 
adjuvant and palliative settings. [1-2]
Despite the benefit of fluoropyrimidine treatment, 
the development of severe toxicities often lead to dose 
reduction, delaying of administration and therapy 
discontinuation. The most common side effects associated 
with 5-FU are diarrhea, mucositis, myelosuppression, 
hand foot syndrome and rarely cardiac toxicity. [3] Grade 
3 or 4 toxicities are reported in about 30% of patients, with 
a mortality rate of 0.5 %. [3, 4] The efforts of establishing 
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effective tests to identify such toxicities preemptively led 
to the development of genotyping or phenotyping methods, 
in order to evaluate the efficiency of the individual 5-FU 
metabolism.[5, 6]
Inside the cell, 5-FU is transformed by different 
enzymes in both active and inactive metabolites. The 
balance between inactive metabolites and therapeutic 
metabolites is thought to be the basis of the inter-
individual differences in toxicity and efficacy of 5-FU 
based treatments.[7]
The dihydropyrimidine dehydrogenase enzyme 
(DPD), encoded by the DPYD gene, inactivates about 
80% of the administrated 5-FU, by transforming it into 
5,6-dihydro-5-fluorouracil. DPYD has been the top 
candidate for pharmacogenetic studies on 5-FU toxicity, 
as a reduced DPD activity results in an increased half-
life of the drug, and thus an increased risk of toxicity. [5, 
8-14] The splice site variant IVS14+1G>A polymorphism 
in the DPYD gene (rs3918290; allele A also known as *2A 
allele) is the most consistent genetic marker for toxicity. 
Unfortunately the low minor allele frequency and the fact 
that just about a 50% of the *2A allele carriers actually 
develop severe toxicity limit its prediction power. [6] In 
a recent published study, conducted on more than 2000 
patients, DPYD*2A polymorphic cases were treated with 
a 50% reduced dose of fluoropyrimidine. The results 
showed a significant reduction of severe toxicity from 73% 
to 28% and with 0% toxic deaths in polymorphic allele 
carriers. [15] However, considering the low frequency 
of DPYD polymorphic allele in general population 
[16], this method could lead to the identification of 
only about 1% of patients at risk of developing severe 
toxicity. DPYD polymorphism is frequently assessed 
in patients eligible for 5-FU treatment together with the 
C677T and the A1298T polymorphisms in the MTHFR 
gene and with the TSER polymorphism in the TS gene. 
In fact,the main mechanism of the 5-FU action consists 
of inhibition of thymidylate synthase (TS) through the 
active metabolite, fluorodeoxyuridine monophosphate 
(FdUMP), which forms an inactive ternary complex with 
TS and 5-10-methylenetetrahydrofolate (MTHF). Optimal 
inhibition of TS requires an elevated level of MTHF, 
which is regulated by the methylenetetrahydrofolate 
reductase enzyme (MTHFR). [7] As a consequence, 
polymorphisms affecting TS and MTHFR levels are 
presumed to be determinants of 5-FU clinical response, 
but indeed their clinical utility is still controversial. [17-
27]
The phenotypic tests available for preemptive 
evaluation of risk for severe toxicity are generally 
less diffused compared to pharmacogenetics, even if 
they could be potentially more effective in identifying 
patients at risk. However, most of such tests are limited 
to detection of DPD activity, not considering possible 
alteration in other 5-FU metabolic enzymes and eventually 
in 5-FU transporters. [7, 28, 29] To overcome this limit, 
we have previously developed a pre-treatment ex-vivo 
assay to determine the velocity at which the peripheral 
blood mononuclear cells (PBMC) metabolize 5-FU. [30] 
This parameter, named individual 5-FU degradation rate 
(5-FUDR, expressed as nmol of drug consumed by cells 
in a time unit), is performed in intact and viable cells, 
thus it the final result of all the enzymatic transformation 
of 5-FU, not just the DPD activity. The individual, pre-
treatment 5-FUDR value, was found to be significantly 
lower in patients who develop grade 3-4 toxicity.[30]
The Oncology Unit of the Sant’Andrea Hospital of 
Rome adopted the pre-treatment 5-FUDR as a routine test 
giving a “toxicity warning” to plan careful monitoring of 
patients with a low 5-FUDR value. In general population, 
the 5-FUDR is a continuous parameter with a normal 
distribution (mean value 1.54 ± 0.41 ng 5-FU/ml/106 
cells/min), whereas the mean 5-FUDR value in carriers 
of the DPYD *2 allele is 0.81±0.29 ng 5-FU/ml/106 cells/
min. [31] We have recently showed that a significant 
reduction of the individual 5-FUDR value is also found 
in subject carriers of a DPYD haplotype involving three 
polymorphisms apart from the *2. [32] Moreover, 5FU-
DR value seems to be related to severe adverse events 
in colorectal cancer patients, with a higher toxicity rate 
when 5-FU degradation is slowed (5-FUDR ≤0.85 ng/
ml/106 cells/min) or accelerated ( 5-FUDR ≥ 2.2 ng/ml/106 
cells/min), regardless of the DPYD status. [31] Since low 
5-FUDR value was also found in subjects who were non 
carriers of defective DPYD alleles, we hypothesized that it 
could identify a further fraction of patients who will likely 
develop severe 5-FU toxicity. 
The present study investigated the association 
between individual 5-FUDR, polymorphisms in DPYD, 
MTHFR,TSER and toxicity in a population of 107 gastric 
and gastro-esophageal junction cancer patients.
PATIENTS AND METHODS
Patients
Patients, with a histological confirmed diagnosis 
of gastric and gastro-esophageal junction cancer, who 
had been undergoing chemotherapy at the Sant’Andrea 
Hospital of Rome in the period 2009-2012, were enrolled 
in this retrospective study. 
The inclusion criteria were: patients with measurable 
disease, adequate organ function and performance status 
of grade 0, 1 or 2 as defined by the Eastern Cooperative 
Oncology Group [33]; patients who had undergone 5-FU 
based chemotherapy (DCF, EOX, FOLFOX, XELOX, 
FOLFIRI); patients who had undergone pre-treatment 
assay of 5-FUDR and characterization of polymorphisms 
of MTHFR, TSER and DPYD genes. Exclusion 
criteria were: relevant diseases within 6 months (i.e.: 
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myocardial infarction, lung fibrosis, etc) and 5-FU based 
chemotherapy in the past.
Chemotherapy cycles were administered every 
2 or 3 weeks according to the scheme. All toxicities 
were graded according to the National Cancer Institute 
Common Terminology Criteria for Adverse Event version 
3 (CTCAE 3.0) and toxicity assessments performed at day 
1 of each cycle until the end of treatment. [34]
The study was conducted in accordance with the 
Declaration of Helsinki and the protocol was approved by 
the institutional ethic committee.
Genotyping
To analyze germinal polymorphisms genomic 
DNA was isolated from peripheral blood, by mean 
of the X-tractor Gene system (Corbett Life Science, 
Australia). The commercial kit for fluoropyrimidine 
response (Diatech, Jesi, Italy) was used, according to the 
manufacturer’s protocol, to analyze the following splice-
site polymorphisms: IVS14+1G>A in the DPYD gene 
and C677T and A1298C SNPs in MTHFR gene. Briefly 
by using PCR with specific primers, the region covering 
the SNP of interest was amplified. Subsequently it was 
sequenced using the Pyrosequencer PyroMark ID system 
(Biotage AB and Biosystems, Uppsala, Sweden). PCR 
(fluoropyrimidine response - Diatech, Jesi, Italy) was used 
also to determine the variable number of tandem repeats 
(VNTR; 2R or 3R) in the thymidylate synthase enhancer 
region (TSER), visualized onto 2,2% agarose gel.
Determination of the individual 5-FU degradation 
rate
The assay for 5-FUDR has been established in 
the Sant’Andrea Hospital of Rome as a routine clinical 
analysis prior to fluorouracil-based chemotherapies and 
is carried out following medical prescription. The test is 
performed, as previously reported [30], using a 5-FUDR 
assay kit (Eureka srl-Lab Division, Chiravalle, Ancona, 
Italy) with a HPLC-MS/MS instrument including an 
Agilent 1100 chromatographic system coupled to an API 
3200 triple quadrupole (ABSCIEX, Framingham, MA, 
USA). Freshly prepared peripheral blood mononuclear 
cells (2.5-3.5 x 106 cells) are incubate with a known dose 
of 5-FU at 37°C, with shaking Cells aliquots are analyzed 
at time 0, 1 h and 2 h. Cells were lysed and centrifuged. 
5-FU concentration in the supernatants is quantified by 
HPLC-MS/MS and the 5-FUDR is expressed as ng 5-FU/
ml/106 cells/min. [30]
Statistical analysis
STATA software, version 11.0 (StataCorp, College 
Station, Tex) was used for statistical analysis Data are 
presented as mean ± standard deviation (SD). Patients 
were categorized by sex, age (<=median age, >median 
age), toxicity (grade 0-2, grade3-4), 5-FUDR value. 
In a previous published study we analyzed the 
continuous variable 5-FUDR on 1010 cancer patients, 
before receiving fluoropyrimidine treatment. [31] Patients 
were classified into the three following metabolic classes, 
according to the values of the 5th and 95th centile as 
determined by the normal distribution of 5-FUDR: poor 
metabolizers (PM; i.e. ≤ 5th centile, ≤0.85 ng/ml/106 cells/
min); normal metabolizers (NM; i.e. > 5th centile and 
< 95th centile, > 0.85 ng/ml/106 cells/min and < 2.2 ng/
ml/106 cells/min); ultra-rapid metabolizers (UM; i.e. ≥ 95th 
centile, ≥ 2.2 ng/ml/106 cells/min).
Chi-squared or Fisher exact test were used to 
establish differences between groups, as appropriate. 
Logistic regression models were useful for univariate 
and multivariate odds ratios (ORs) with associated 95% 
confidence intervals (CI) for variables associated with 
severe toxicities.
Test for deviation of polymorphisms’ distributions 
from the Hardy-Weinberg (HW) equilibrium was 
performed using the SNP Stats software. [35]
RESULTS
We analyzed gene polymorphisms related to 5-FU 
response and the pretreatment 5-FUDR in 107 gastro-
esophageal cancer patients (71 males, median age 68/69 
years; 36 females, median age 64/65 years) Table 1.. Major 
adverse events (CTC-grade 3 or 4) were encountered in 
29 patients (27.1 %). The distributions of the analyzed 
gene polymorphisms (Table 2) were in Hardy-Weinberg 
equilibrium. The DPYD *2 allele was detected in just 
one heterozygous carrier, corresponding with the 1.28% 
frequency reported for the overall Italian population [32], 
hence this polymorphism has not been further considered 
in the analysis. However, this patient had a 5-FUDR below 
the 5th centile (0.58 ng/ml/106 cells/min) and developed 
a high grade toxicity. In the total samples analyzed, the 
5-FUDR has a mean value of 1.61 ± 0.42 ng/ml/106 cells/
min, and is not significantly affected by age, gender, 
MTHFR A1298T or C677T polymorphisms nor by the 
TSER polymorphism (Table 1). 
Table 3 reports the toxicities. Table 4 reports the 
distribution of low toxicity (grade 0-2) and severe toxicity 
(grade 3-4) among patients’ groups. Whereas neither sex, 
age categories, nor MTHFR and TSER genotype affect 
the development of higher grade toxicity. The 5-FUDR 
value is associated with the development of severe 5-FU 
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toxicities. In particular, a significant increase (p=0.002) 
in the proportion of severe toxicities has been detected in 
both the patients’ group with a 5-FUDR poor metabolizers 
and for the patients’ group with a 5-FUDR ultra-rapid 
metabolizers The ORs adjusted for age and sex were 
11.14 (95%CI 1.09-113.77) for the low 5-FU metabolizers 
and 9.63 (95%CI 1.70-54.55) for the ultra-rapid 5-FU 
metabolizers.
DISCUSSION
Due to the narrow therapeutic range of 
fluoropyrimidines, the ratio of the effective dose to toxic 
dose is small [36] and the risk of developing severe 
toxicity, with a small percentage of lethal events [3, 4], 
is a main concern for patients and oncologists. Despite 
the improvement led by the advent of pharmacogenetic 
screening for DPYD, the proportion of pre-emptive 
identification of patients at high risk of severe (grade 
G3-4) 5-FU toxicity is still inadequate. Against a 30% 
of grade 3-4 toxicities [3, 4], the DPYD polymorphisms 
identify about 1-3% of patients at risk, because of the low 
frequencies of specific alleles in the general population.[6, 
32] Thus, we investigated the potential of the phenotypic 
test 5-FUDR to increase the detection of “high risk” 
patients prior to 5-FU administration, in order to plan 
careful monitoring of toxic effects and better manage the 
anti-cancer therapy.
Along with the normal distribution of the 5-FUDR 
value, two cut-off values associated with a significant 
higher risk for the onset of grade 3-4 toxicity were 
identified: the 5thand the 95thcentiles (0.85 and 2.2 ng/
ml/106 cells/min, respectively). [31] In fact, in the 
analyzed cohort, subjects with a poor 5-FU metabolism 
present an 11.14 OR (95%CI 1.09-113.77) for grade 
3-4 toxicity. The underlying toxicity mechanism in poor 
5-FU metabolizers could be explained by decreased drug 
clearance, as also suggested by the association between 
low 5-FUDR values and the presence of defective DPYD 
Table 1: Patients’ characteristics.





≤ median 56 52.34
>median 51 47.66
Site of primary
Gastro-oesophageal junction 11 10.28
Gastric 96 89.72
Stage
Locally advanced 49 45.79
Metastatic 58 54.20
Type of treatment
5-FU based 59 55.14
Capecitabine based 10 9.35
Monotherapy 38 35.51
*for males 68/69yrs; for females 64/65yrs.








































































Hematological 16 14.95 20 18.69
Gastrointestinal 23 21.50 8 7.48
HFS 1 0.93 1 0.93
Other 15 14.02 2 1.87
Table 4: Distribution of grade 0-2 and grade 3-4 toxicities according to demographics, genetics and 5-FUDR
Total ToxicityGrade 0-2
Toxicity
Grade 3-4 p OR (95% CI)* OR (95% CI)**















































































































































*Crude odds ratio; **Odds ratio adjusted for age and gender; ***for males 68/69yrs; for females 64/65yrs.
Figure 1: 5-Fluorouracil metabolism.
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alleles [5, 7, 9, 17], namely the *2A allele and the Hap7 
haplotype [32]. However, this previous work showed 
that subjects who are carriers of normal DPYD alleles 
(concerning 15 analyzed SNPs) can anyway have a poor 
5-FUDR. The present results support the hypothesis that, 
regardless the DPYD genotype, the 5-FUDR is a predictor 
of toxicities related to fluorouracil-based chemotherapies, 
and a parameter reflecting the overall fluoropyrimidine 
metabolism.
Interestingly, we also found an association between 
ultra-rapid (5-FUDR > 95th centile) 5-FU metabolism 
(9.63 OR, 95%CI 1.70-54.55) with grade 3-4 toxicity. 
Theoretically, a high 5-FUDR could be due to an increased 
activity of the inactivating enzymes DPD, leading to a 
decline in the drug percentage transformed into active 
metabolites. However, a similar fast metabolism could 
derive by an increased activity of the 5-FU activating 
enzymes, leading to a raise in the concentration of 
therapeutic molecules. (Figure 1). Indeed, it has been 
demonstrated that the sensitivity to 5-FU is affected by 
polymorphisms in the orotate phosphoribosyltransferase 
gene (OPRT, transforming 5-FU in 5-fluorouridine 
monophosphate) and, in cancer tissues, by the level of 
activity of the OPRT enzyme and by the OPRT/DPD 
activities ratio. [37-40]
Since increased concentration of active metabolites 
could affect response as well as toxicity of the 5-FU 
treatment, it could be speculated that ultra-rapid 5-FU 
metabolizers could also have a different prognosis 
compared to non-ultrarapid metabolizers. This hypothesis 
is currently under investigation.
A limitation of our study is the enrollment of 
patients treated with combination therapy, even though 
to date the studies of associations between DPYD 
polymorphisms and 5-FU toxicities were based on 5-FU 
based chemotherapy instead of only 5-FU monotherapy. 
Furthermore, in clinical practice only a few 
percentage of patients are treated with monotherapy 
so it’s not easy to understand clear which toxicities 
depends on 5 -fluorouracil or on other drugs. However we 
presented at ESMO 2015 our results of patients treated 
with capecitabine monotherapy and it was confirmed the 
association between 5-FUDR classes and toxicity. [41]
The poor and ultra-rapid 5-FU metabolizer classes 
include by definition a 10% (< 5th centile and > 95% 
centile) of the overall population. Thus, if used as a 
predictive factor, it has the potentiality to sensibly increase 
the identification of “at risk” patients, compared to 
pharmacogenetic testing. In the analyzed cohort of gastro-
esophageal cancer patients, the 5-FUDR test classified 11 
out of 107 subjects as patients with a consistent risk to 
develop grade 3-4 toxicity, of which 7 (63.6%) actually 
developed severe toxicity. The proportion of patients 
who developed severe toxicity identified preemptively by 
the 5-FUDR tests is 24.1% (7/29), a significant progress 
compared to the low percentage of toxicity potentially 
identifiable by the commonly used DPYD polymorphisms. 
Considering that the 5-FUDR assay is a low-cost test 
(about 10 € per sample), it requires non-invasive sampling 
methods, and test results are available in one working day, 
it appears suitable and cost-effective for implementation 
in the routine pre-treatment panel of clinical evaluations.
Despite the limitations of the presented 
retrospective study, we observed appealing results. So, 
as future perspective, we highlight the importance of 
conducting prospective studies on larger sample size, on 
a homogeneous population in order to evaluate 5-FUDR 
impact on outcomes and with pharmacokinetics analysis 
on fluorouracil metabolites plasma concentration. More 
data on others cancer types, treated with fluoropyrimidine, 
are also auspicated.
CONCLUSIONS
Compared to the available pharmacogenomic 
screening, the pre-treatment evaluation of 5-FUDR 
increases considerably the proportion of identified gastro-
esophageal cancer patients at high risk for severe 5-FU 
toxicity, such as in colorectal cancer patients’ cohort 
preemptively.
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